Training Example: TRODELVY (Gilead Sciences, Inc.) – Review the Data, Give Your Score & Compare to the Real AI Evaluation

[H6]

[H3] WHAT IS TRODELVY?
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with:
triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.
hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body or cannot be removed by surgery, and who previously received endocrine therapy and at least two additional treatments for metastatic disease.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.
[H3] Important Safety Information
TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:
Low white blood cell count (neutropenia) is common and can sometimes be severe and lead to infections that can be life-threatening or cause death as early as the first cycle of treatment. Your healthcare provider should check your blood cell counts during treatment and may give a medicine to help prevent neutropenia starting in the first cycle of treatment if you have an increased risk for developing low white blood cell count with a fever (febrile neutropenia). If your white blood cell count is too low, your healthcare provider may need to delay treatment or lower your dose, give you a medicine to treat low blood cell count, or in some cases may permanently stop TRODELVY. Your healthcare provider may need to give you antibiotic medicines if you develop fever while your white blood cell count is low. Call your healthcare provider right away if you develop any of the following signs of infection: fever, chills, cough, shortness of breath, or burning or pain when you urinate.
Severe diarrhea. Diarrhea is common and can be severe. Severe diarrhea can lead to loss of too much body fluid (dehydration) and kidney problems. Your healthcare provider should monitor you for diarrhea and give you medicine as needed to help control it. If you lose too much body fluid, your healthcare provider may need to give you fluids and electrolytes to replace body salts. If you develop diarrhea during your treatment with TRODELVY, your healthcare provider should check to see if it may be caused by an infection. Your healthcare provider may decrease your dose, delay treatment, or permanently stop TRODELVY if your diarrhea is severe and cannot be controlled with anti-diarrheal medicines.
Call your healthcare provider right away the first time that you get diarrhea during treatment with TRODELVY; if you have black or bloody stools; if you have symptoms of dehydration, such as lightheadedness, dizziness, or faintness; if you are unable to take fluids by mouth due to nausea or vomiting; or if you are not able to get your diarrhea under control within 24 hours.

Do not receive TRODELVY if you have had a severe allergic reaction to TRODELVY. Ask your healthcare provider if you are not sure.
Allergic and infusion-related reactions which can be serious and life-threatening. Tell your healthcare provider or nurse right away if you get any of the following symptoms during your infusion of TRODELVY or within 24 hours after: swelling of your face, lips, tongue, or throat; hives; skin rash, itching, or flushing of your skin; fever; difficulty breathing or wheezing; lightheadedness, dizziness, feeling faint, or pass out; or chills or shaking chills (rigors).
Nausea and vomiting are common with TRODELVY and can sometimes be severe. Before each dose of TRODELVY, you will receive medicines to help prevent nausea and vomiting along with medicines to take home with instructions about how to take them. Call your healthcare provider right away if you have nausea or vomiting that is not controlled with the medicines prescribed for you. Your healthcare provider may decide to decrease your dose or stop TRODELVY if your nausea and vomiting is severe and cannot be controlled with anti-nausea medicines.
Before receiving TRODELVY, tell your healthcare provider about all of your medical conditions, including if you:
have been told that you carry a gene for UGT1A1*28, which can increase your risk of getting side effects with TRODELVY, especially low white blood cell counts, with or without a fever, and low red blood cell counts.
have liver problems.
are pregnant or plan to become pregnant. TRODELVY can harm your unborn baby. Your healthcare provider should check to see if you are pregnant before you start receiving TRODELVY. TRODELVY may cause fertility problems in females, which could affect your ability to have a baby. Talk to your healthcare provider if fertility is a concern for you.
Females who can become pregnant should use effective birth control during treatment and for 6 months after your last dose of TRODELVY. Talk to your healthcare provider about birth control choices that may be right for you during this time. Tell your healthcare provider right away if you become pregnant during treatment with TRODELVY.
Males with a female partner who can become pregnant should use effective birth control during treatment and for 3 months after your last dose of TRODELVY.

are breastfeeding or plan to breastfeed. It is not known if TRODELVY passes into your breastmilk and can harm your baby. Do not breastfeed during treatment and for 1 month after your last dose of TRODELVY.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the way TRODELVY works.
The most common side effects of TRODELVY include decreased white blood cell (leukocyte and lymphocyte) and red blood cell counts, feeling tired or weak, hair loss, constipation, increased sugar levels in the blood, decreased protein levels (albumin) in the blood, decreased appetite, changes in kidney function test, increased levels of enzyme called alkaline phosphatase in the blood (test for liver or bone problems), and decreased levels of magnesium, potassium, and sodium in the blood.
These are not all of the possible side effects of TRODELVY. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click to see Important Facts about TRODELVY, including Important Warning.

[H6]

[H2] You are now leaving TRODELVY.com

Click OK to proceed or Cancel to return to TRODELVY.com

Select a cancer type to learn more.

info
HR+/HER2- Metastatic Breast Cancer
close
TRODELVY is a prescription medicine used to treat adults with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who previously received endocrine therapy and at least two additional treatments for metastatic disease.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.
Continue
arrow_forward

HR+/HER2- Metastatic Breast Cancer

info
Metastatic Triple-Negative Breast Cancer
close
TRODELVY is a prescription medicine used to treat adults with triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.
Continue
arrow_forward

Metastatic Triple-Negative Breast Cancer

[IMG: A White man, a White woman, and an Asian woman in their 60s are sitting at a dining table, laughing as they play a board game. Actor portrayals.]

Actor portrayals.

Tap for Important Safety Information. TRODELVY can cause serious side effects, including low white blood cell count and diarrhea.

[H3] What is trodelvy?

[H3] important safety information
TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:

Expand
[IMG: isi-expand-icon]

Close
[IMG: isi-collapse-icon]

Tap for Important Safety Information. TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:

Expand
[IMG: isi-expand-white-icon]

Close
[IMG: isi-collapse-white-icon]

[H3] What is Trodelvy?
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with:
triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.
hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body or cannot be removed by surgery, and who previously received endocrine therapy and at least two additional treatments for metastatic disease.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.

[H3] IMPORTANT SAFETY INFORMATION
TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:
Low white blood cell count (neutropenia) is common and can sometimes be severe and lead to infections that can be life-threatening or cause death as early as the first cycle of treatment. Your healthcare provider should check your blood cell counts during treatment and may give a medicine to help prevent neutropenia starting in the first cycle of treatment if you have an increased risk for developing low white blood cell count with a fever (febrile neutropenia). If your white blood cell count is too low, your healthcare provider may need to delay treatment or lower your dose, give you a medicine to treat low blood cell count, or in some cases may permanently stop TRODELVY. Your healthcare provider may need to give you antibiotic medicines if you develop fever while your white blood cell count is low. Call your healthcare provider right away if you develop any of the following signs of infection: fever, chills, cough, shortness of breath, or burning or pain when you urinate.
Severe diarrhea. Diarrhea is common and can be severe. Severe diarrhea can lead to loss of too much body fluid (dehydration) and kidney problems. Your healthcare provider should monitor you for diarrhea and give you medicine as needed to help control it. If you lose too much body fluid, your healthcare provider may need to give you fluids and electrolytes to replace body salts. If you develop diarrhea during your treatment with TRODELVY, your healthcare provider should check to see if it may be caused by an infection. Your healthcare provider may decrease your dose, delay treatment, or permanently stop TRODELVY if your diarrhea is severe and cannot be controlled with anti-diarrheal medicines.
Call your healthcare provider right away the first time that you get diarrhea during treatment with TRODELVY; if you have black or bloody stools; if you have symptoms of dehydration, such as lightheadedness, dizziness, or faintness; if you are unable to take fluids by mouth due to nausea or vomiting; or if you are not able to get your diarrhea under control within 24 hours.

Do not receive TRODELVY if you have had a severe allergic reaction to TRODELVY. Ask your healthcare provider if you are not sure.
Allergic and infusion-related reactions can be serious and life-threatening. Tell your healthcare provider or nurse right away if you get any of the following symptoms during your infusion of TRODELVY or within 24 hours after: swelling of your face, lips, tongue, or throat; hives; skin rash, itching, or flushing of your skin; fever; difficulty breathing or wheezing; lightheadedness, dizziness, feeling faint, or pass out; or chills or shaking chills (rigors).
Nausea and vomiting are common and can sometimes be severe. Before each dose of TRODELVY, you will receive medicines to help prevent nausea and vomiting along with medicines to take home with instructions about how to take them. Call your healthcare provider right away if you have nausea or vomiting that is not controlled with the medicines prescribed for you. Your healthcare provider may decide to decrease your dose, delay treatment, or permanently stop TRODELVY if your nausea and vomiting is severe and cannot be controlled with anti-nausea medicines.
Before receiving TRODELVY, tell your healthcare provider about all of your medical conditions, including if you:
have been told that you carry a gene for UGT1A1*28, which can increase your risk of getting side effects with TRODELVY, especially low white blood cell counts, with or without a fever, and low red blood cell counts.
have liver problems.
are pregnant or plan to become pregnant. TRODELVY can harm your unborn baby. Your healthcare provider should check to see if you are pregnant before you start receiving TRODELVY. TRODELVY may cause fertility problems in females, which could affect your ability to have a baby. Talk to your healthcare provider if fertility is a concern for you.
Females who can become pregnant should use effective birth control during treatment and for 6 months after your last dose of TRODELVY. Talk to your healthcare provider about birth control choices that may be right for you during this time. Tell your healthcare provider right away if you become pregnant during treatment with TRODELVY.
Males with a female partner who can become pregnant should use effective birth control during treatment and for 3 months after your last dose of TRODELVY.

are breastfeeding or plan to breastfeed. It is not known if TRODELVY passes into your breastmilk and can harm your baby. Do not breastfeed during treatment and for 1 month after your last dose of TRODELVY.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the way

[H6]

[H3] WHAT IS TRODELVY?
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who previously received endocrine therapy and at least two additional treatments for metastatic disease.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.
[H3] Important Safety Information
TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:
Low white blood cell count (neutropenia) is common and can sometimes be severe and lead to infections that can be life-threatening or cause death as early as the first cycle of treatment. Your healthcare provider should check your blood cell counts during treatment and may give a medicine to help prevent neutropenia starting in the first cycle of treatment if you have an increased risk for developing low white blood cell count with a fever (febrile neutropenia). If your white blood cell count is too low, your healthcare provider may need to delay treatment or lower your dose, give you a medicine to treat low blood cell count, or in some cases may permanently stop TRODELVY. Your healthcare provider may need to give you antibiotic medicines if you develop fever while your white blood cell count is low. Call your healthcare provider right away if you develop any of the following signs of infection: fever, chills, cough, shortness of breath, or burning or pain when you urinate.
Severe diarrhea. Diarrhea is common and can be severe. Severe diarrhea can lead to loss of too much body fluid (dehydration) and kidney problems. Your healthcare provider should monitor you for diarrhea and give you medicine as needed to help control it. If you lose too much body fluid, your healthcare provider may need to give you fluids and electrolytes to replace body salts. If you develop diarrhea during your treatment with TRODELVY, your healthcare provider should check to see if it may be caused by an infection. Your healthcare provider may decrease your dose, delay treatment, or permanently stop TRODELVY if your diarrhea is severe and cannot be controlled with anti-diarrheal medicines.
Call your healthcare provider right away the first time that you get diarrhea during treatment with TRODELVY; if you have black or bloody stools; if you have symptoms of dehydration, such as lightheadedness, dizziness, or faintness; if you are unable to take fluids by mouth due to nausea or vomiting; or if you are not able to get your diarrhea under control within 24 hours.

Do not receive TRODELVY if you have had a severe allergic reaction to TRODELVY. Ask your healthcare provider if you are not sure.
Allergic and infusion-related reactions which can be serious and life-threatening. Tell your healthcare provider or nurse right away if you get any of the following symptoms during your infusion of TRODELVY or within 24 hours after: swelling of your face, lips, tongue, or throat; hives; skin rash, itching, or flushing of your skin; fever; difficulty breathing or wheezing; lightheadedness, dizziness, feeling faint, or pass out; or chills or shaking chills (rigors).
Nausea and vomiting are common with TRODELVY and can sometimes be severe. Before each dose of TRODELVY, you will receive medicines to help prevent nausea and vomiting along with medicines to take home with instructions about how to take them. Call your healthcare provider right away if you have nausea or vomiting that is not controlled with the medicines prescribed for you. Your healthcare provider may decide to decrease your dose or stop TRODELVY if your nausea and vomiting is severe and cannot be controlled with anti-nausea medicines.
Before receiving TRODELVY, tell your healthcare provider about all of your medical conditions, including if you:
have been told that you carry a gene for UGT1A1*28, which can increase your risk of getting side effects with TRODELVY, especially low white blood cell counts, with or without a fever, and low red blood cell counts.
have liver problems.
are pregnant or plan to become pregnant. TRODELVY can harm your unborn baby. Your healthcare provider should check to see if you are pregnant before you start receiving TRODELVY. TRODELVY may cause fertility problems in females, which could affect your ability to have a baby. Talk to your healthcare provider if fertility is a concern for you.
Females who can become pregnant should use effective birth control during treatment and for 6 months after your last dose of TRODELVY. Talk to your healthcare provider about birth control choices that may be right for you during this time. Tell your healthcare provider right away if you become pregnant during treatment with TRODELVY.
Males with a female partner who can become pregnant should use effective birth control during treatment and for 3 months after your last dose of TRODELVY.

are breastfeeding or plan to breastfeed. It is not known if TRODELVY passes into your breastmilk and can harm your baby. Do not breastfeed during treatment and for 1 month after your last dose of TRODELVY.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the way TRODELVY works.
The most common side effects of TRODELVY include decreased white blood cell (leukocyte and lymphocyte) and red blood cell counts, feeling tired or weak, hair loss, constipation, increased sugar levels in the blood, decreased protein levels (albumin) in the blood, decreased appetite, changes in kidney function test, increased levels of enzyme called alkaline phosphatase in the blood (test for liver or bone problems), and decreased levels of magnesium, potassium, and sodium in the blood.
These are not all of the possible side effects of TRODELVY. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click to see Important Facts about TRODELVY, including Important Warning.

[H6]

[H2] You are now leaving TRODELVY.com

Click OK to proceed or Cancel to return to TRODELVY.com

[IMG: A White woman in her 60s with short blonde hair is sitting on the couch hugging her baby grandchild and smiling softly. Beside her, a White woman in her 30s rests her head on the couch and smiles. Actor portrayals.]

Hear from people
receiving TRODELVY.
Patient Stories
Actor portrayals.

Actor portrayals.

[IMG: A White woman in her 60s with short blonde hair is sitting on the couch hugging her baby grandchild and smiling softly. Beside her, a White woman in her 30s rests her head on the couch and smiles. Actor portrayals.]

In the phase 3 clinical trial, half of patients receiving TRODELVY were alive at 14.4 months compared with 11.2 months for traditional chemotherapy (median overall survival). The clinical trial included 543 adults with previously treated* HR+/HER2- mBC (272 on TRODELVY, 271 on traditional chemotherapy, including eribulin, capecitabine, gemcitabine, or vinorelbine). Half of patients receiving TRODELVY lived without their cancer growing, spreading, or getting worse for 5.5 months compared with 4.0 months for those receiving traditional chemo (median progression-free survival).
*Previous treatments included at least 1 hormone/endocrine therapy, a CDK4/6 inhibitor, and a taxane in any treatment setting (neoadjuvant, adjuvant, or metastatic), and 2 to 4 prior chemotherapies for metastatic disease (1 could have been given as a neoadjuvant or adjuvant treatment if recurrence occurred within 12 months).

Hear from people receiving TRODELVY.
Patient Stories

[H2] TRODELVY for pretreated HR+/HER2- mBC

[IMG: how-it-works-icon-teal-dsk]

[IMG: efficacy-results-icon-teal-dsk]

[IMG: discussion-guide-download-icon-teal]

Woman 1 VO:
When my hormone treatment stopped working for HR+/HER2- metastatic breast cancer, everything stopped.
<TEXT ON-SCREEN>
Metastatic cancer is cancer that has spread to other parts of the body.
Actor portrayals.
<END OF TEXT ON-SCREEN>
Woman 1 VO:
So what keeps me going? This.
<TEXT ON-SCREEN>
This
<END OF TEXT ON-SCREEN>
Woman 2 VO:
This is why I choose TRODELVY.
<TEXT ON-SCREEN>
This
TRODELVY®
(sacituzumab govitecan-hziy)
180 mg for injection
<END OF TEXT ON-SCREEN>
Narrator VO:
TRODELVY is for adults with HR+/HER2- metastatic breast cancer who have received hormone therapy and at least two additional treatments for metastatic disease.
<TEXT ON-SCREEN>
TRODELVY is by prescription only.
<END OF TEXT ON-SCREEN>
Narrator VO:
TRODELVY is designed differently and
<TEXT ON-SCREEN>
Different from traditional chemo
<END OF TEXT ON-SCREEN>
Narrator VO:
was proven to help some people live longer than chemotherapy.
<TEXT ON-SCREEN>
In the clinical trial, half of patients receiving TRODELVY were alive at 14 months compared with 11 months for traditional chemo.
<END OF TEXT ON-SCREEN>
Narrator VO:
TRODELVY can cause severe or life-threatening side effects, including low white blood cell count, which can lead to infections, diarrhea, and allergic reactions. Do not take TRODELVY if you are allergic to it.
<TEXT ON-SCREEN>
TRODELVY can cause severe or life-threatening side effects, including low white blood cell count, which can lead to infections; diarrhea and allergic reactions.
<END OF TEXT ON-SCREEN>
Narrator VO:
Other serious side effects include nausea, vomiting, and infusion reactions. Tell your doctor right away if you experience any signs of infection while taking TRODELVY, if you are or plan to be pregnant or breastfeeding, or if you have liver problems. Tell your doctor about all your medical conditions and all the medicines and supplements you take.
<TEXT ON-SCREEN>
Do not take TRODELVY if you are allergic to it. Other serious side effects include nausea, vomiting, and infusion reactions. Tell your doctor right away if you experience any signs of infection while taking TRODELVY, if you are or plan to be pregnant or breastfeeding, or if you have liver problems. Tell your doctor about all your medical conditions and all the medicines and supplements you take.
<END OF TEXT ON-SCREEN>
Narrator VO:
There are other side effects of TRODELVY.
<TEXT ON-SCREEN>
There are other side effects of TRODELVY.
<END OF TEXT ON-SCREEN>
Woman 3 VO:
This is why I choose TRODELVY.
<TEXT ON-SCREEN>
This
<END OF TEXT ON-SCREEN>
Narrator VO:
Ask your doctor about TRODELVY.
<TEXT ON-SCREEN>
TRODELVY®
sacituzumab govitecan-hziy
180 mg for injection
(troh-DELL-vee)
Visit TRODELVY.com for more information, including financial support
1-877-7-TRODELVY | Gileadpriceinfo.com
GILEAD
<END OF TEXT ON-SCREEN>

Back to top

[H3] What is Trodelvy?
[H3] important safety information
TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:

Expand
[IMG: isi-expand-icon]

Close
[IMG: isi-collapse-icon]

Tap for Important Safety Information. TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:

Expand
[IMG: isi-expand-white-icon]

Close
[IMG: isi-collapse-white-icon]

[H3] What is Trodelvy?
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who previously received endocrine therapy and at least two additional treatments for metastatic disease.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.

[H3] IMPORTANT SAFETY INFORMATION
TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:
Low white blood cell count (neutropenia) is common and can sometimes be severe and lead to infections that can be life-threatening or cause death as early as the first cycle of treatment. Your healthcare provider should check your blood cell counts during treatment and may give a medicine to help prevent neutropenia starting in the first cycle of treatment if you have an increased risk for developing low white blood cell count with a fever (febrile neutropenia). If your white blood cell count is too low, your healthcare provider may need to delay treatment or lower your dose, give you a medicine to treat low blood cell count, or in some cases may permanently stop TRODELVY. Your healthcare provider may need to give you antibiotic medicines if you develop fever while your white blood cell count is low. Call your healthcare provider right away if you develop any of the following signs of infection: fever, chills, cough, shortness of breath, or burning or pain when you urinate.
Severe diarrhea. Diarrhea is common and can be severe. Severe diarrhea can lead to loss of too much body fluid (dehydration) and kidney problems. Your healthcare provider should monitor you for diarrhea and give you medicine as needed to help control it. If you lose too much body fluid, your healthcare provider may need to give you fluids and electrolytes to replace body salts. If you develop diarrhea during your treatment with TRODELVY, your healthcare provider should check to see if it may be caused by an infection. Your healthcare provider may decrease your dose, delay treatment, or permanently stop TRODELVY if your diarrhea is severe and cannot be controlled with anti-diarrheal medicines.
Call your healthcare provider right away the first time that you get diarrhea during treatme

[H6]

[H3] WHAT IS TRODELVY?
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.
[H3] Important Safety Information
TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:
Low white blood cell count (neutropenia) is common and can sometimes be severe and lead to infections that can be life-threatening or cause death as early as the first cycle of treatment. Your healthcare provider should check your blood cell counts during treatment and may give a medicine to help prevent neutropenia starting in the first cycle of treatment if you have an increased risk for developing low white blood cell count with a fever (febrile neutropenia). If your white blood cell count is too low, your healthcare provider may need to delay treatment or lower your dose, give you a medicine to treat low blood cell count, or in some cases may permanently stop TRODELVY. Your healthcare provider may need to give you antibiotic medicines if you develop fever while your white blood cell count is low. Call your healthcare provider right away if you develop any of the following signs of infection: fever, chills, cough, shortness of breath, or burning or pain when you urinate.
Severe diarrhea. Diarrhea is common and can be severe. Severe diarrhea can lead to loss of too much body fluid (dehydration) and kidney problems. Your healthcare provider should monitor you for diarrhea and give you medicine as needed to help control it. If you lose too much body fluid, your healthcare provider may need to give you fluids and electrolytes to replace body salts. If you develop diarrhea during your treatment with TRODELVY, your healthcare provider should check to see if it may be caused by an infection. Your healthcare provider may decrease your dose, delay treatment, or permanently stop TRODELVY if your diarrhea is severe and cannot be controlled with anti-diarrheal medicines.
Call your healthcare provider right away the first time that you get diarrhea during treatment with TRODELVY; if you have black or bloody stools; if you have symptoms of dehydration, such as lightheadedness, dizziness, or faintness; if you are unable to take fluids by mouth due to nausea or vomiting; or if you are not able to get your diarrhea under control within 24 hours.

Do not receive TRODELVY if you have had a severe allergic reaction to TRODELVY. Ask your healthcare provider if you are not sure.
Allergic and infusion-related reactions which can be serious and life-threatening. Tell your healthcare provider or nurse right away if you get any of the following symptoms during your infusion of TRODELVY or within 24 hours after: swelling of your face, lips, tongue, or throat; hives; skin rash, itching, or flushing of your skin; fever; difficulty breathing or wheezing; lightheadedness, dizziness, feeling faint, or pass out; or chills or shaking chills (rigors).
Nausea and vomiting are common with TRODELVY and can sometimes be severe. Before each dose of TRODELVY, you will receive medicines to help prevent nausea and vomiting along with medicines to take home with instructions about how to take them. Call your healthcare provider right away if you have nausea or vomiting that is not controlled with the medicines prescribed for you. Your healthcare provider may decide to decrease your dose or stop TRODELVY if your nausea and vomiting is severe and cannot be controlled with anti-nausea medicines.
Before receiving TRODELVY, tell your healthcare provider about all of your medical conditions, including if you:
have been told that you carry a gene for UGT1A1*28, which can increase your risk of getting side effects with TRODELVY, especially low white blood cell counts, with or without a fever, and low red blood cell counts.
have liver problems.
are pregnant or plan to become pregnant. TRODELVY can harm your unborn baby. Your healthcare provider should check to see if you are pregnant before you start receiving TRODELVY. TRODELVY may cause fertility problems in females, which could affect your ability to have a baby. Talk to your healthcare provider if fertility is a concern for you.
Females who can become pregnant should use effective birth control during treatment and for 6 months after your last dose of TRODELVY. Talk to your healthcare provider about birth control choices that may be right for you during this time. Tell your healthcare provider right away if you become pregnant during treatment with TRODELVY.
Males with a female partner who can become pregnant should use effective birth control during treatment and for 3 months after your last dose of TRODELVY.

are breastfeeding or plan to breastfeed. It is not known if TRODELVY passes into your breastmilk and can harm your baby. Do not breastfeed during treatment and for 1 month after your last dose of TRODELVY.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the way TRODELVY works.
The most common side effects of TRODELVY include decreased white blood cell (leukocyte and lymphocyte) and red blood cell counts, feeling tired or weak, hair loss, constipation, increased sugar levels in the blood, decreased protein levels (albumin) in the blood, decreased appetite, changes in kidney function test, increased levels of enzyme called alkaline phosphatase in the blood (test for liver or bone problems), and decreased levels of magnesium, potassium, and sodium in the blood.
These are not all of the possible side effects of TRODELVY. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click to see Important Facts about TRODELVY, including Important Warning.

[H6]

[H2] You are now leaving TRODELVY.com

Click OK to proceed or Cancel to return to TRODELVY.com

[IMG: A Black woman in her 40s with short natural hair is cuddled on the living room couch with her family—a Black man in his 40s and their 2 preteen daughters. The woman has her arms around both of her daughters and is smiling at her husband. The family is close, leaning on each other and smiling. Actor portrayals.]

Hear from peoplereceiving TRODELVY.
Patient Stories

Actor portrayals.

Actor portrayals.

[IMG: A Black woman in her 40s with short natural hair is cuddled on the living room couch with her family—a Black man in his 40s and their 2 preteen daughters. The woman has her arms around both of her daughters and is smiling at her husband. The family is close, leaning on each other and smiling. Actor portrayals.]

In the phase 3 clinical trial, half of patients receiving TRODELVY were alive at 11.8 months compared with 6.9 months for traditional chemotherapy (median overall survival). The clinical trial included 529 adults with previously treated mTNBC (267 on TRODELVY, 262 on traditional chemotherapy, including eribulin, capecitabine, gemcitabine, or vinorelbine). Half of patients receiving TRODELVY lived without cancer progression for 4.8 months compared with 1.7 months for those receiving traditional chemotherapy (median progression-free survival).

Hear from people receiving TRODELVY.
Patient Stories

[H2] TRODELVY for pretreated mTNBC

[IMG: how-it-works-icon-teal-dsk]

[IMG: efficacy-results-icon-teal-dsk]

[IMG: discussion-guide-download-icon-teal]

<TEXT ON-SCREEN>
Metastatic cancer is cancer that has spread to other parts of the body.
Actor portrayals.
<END OF TEXT ON-SCREEN>
Woman 1 VO:
Metastatic triple-negative breast cancer—it felt like my world stopped. So what keeps me going? This.
<TEXT ON-SCREEN>
This
<END OF TEXT ON-SCREEN>
Woman 2 VO:
This.
<TEXT ON-SCREEN>
This
<END OF TEXT ON-SCREEN>
Woman 3 VO:
This is why I choose TRODELVY.
<TEXT ON-SCREEN>
This
TRODELVY®
(sacituzumab govitecan-hziy)
180 mg for injection
<END OF TEXT ON-SCREEN>
Narrator VO:
TRODELVY is for adults with metastatic triple-negative breast cancer who have received two or more prior treatments, including at least one for metastatic disease.
<TEXT ON-SCREEN>
TRODELVY is by prescription only.
<END OF TEXT ON-SCREEN>
<TEXT ON-SCREEN>
Different from traditional chemo
<END OF TEXT ON-SCREEN>
Narrator VO:
TRODELVY is designed differently and
<TEXT ON-SCREEN>
In the clinical trial, half of patients receiving TRODELVY were alive at 12 months compared with 7 months for traditional chemo.
<END OF TEXT ON-SCREEN>
Narrator VO:
was proven to help some people live longer than chemotherapy.
TRODELVY can cause severe or life-threatening side effects, including low white blood cell count, which can lead to infections, diarrhea, and allergic reactions. Do not take TRODELVY if you are allergic to it.
<TEXT ON-SCREEN>
TRODELVY can cause severe or life-threatening side effects, including low white blood cell count, which can lead to infections; diarrhea and allergic reactions. Do not take TRODELVY if you are allergic to it.
<END OF TEXT ON-SCREEN>
Narrator VO:
Other serious side effects include nausea, vomiting, and infusion reactions. Tell your doctor right away if you experience any signs of infection while taking TRODELVY, if you are or plan to be pregnant or breastfeeding, or if you have liver problems. Tell your doctor about all your medical conditions and all the medicines and supplements you take.
<TEXT ON-SCREEN>
Other serious side effects include nausea, vomiting, and infusion reactions. Tell your doctor right away if you experience any signs of infection while taking TRODELVY, if you are or plan to be pregnant or breastfeeding, or if you have liver problems. Tell your doctor about all your medical conditions and all the medicines and supplements you take.
<END OF TEXT ON-SCREEN>
Narrator VO:
There are other side effects of TRODELVY.
<TEXT ON-SCREEN>
There are other side effects of TRODELVY.
<END OF TEXT ON-SCREEN>
Woman 1 VO:
This is what it’s all about.
<TEXT ON-SCREEN>
This
<END OF TEXT ON-SCREEN>
Narrator VO:
Ask your doctor about TRODELVY.
<TEXT ON-SCREEN>
TRODELVY®
(sacituzumab govitecan-hziy)
180 mg for injection
(troh-DELL-vee)
Visit TRODELVY.com
for more information, including financial support
1-877-7-TRODELVY | Gileadpriceinfo.com
GILEAD
<END OF TEXT ON-SCREEN>

Back to top

[H3] What is trodelvy?

[H3] important safety information
TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:

Expand
[IMG: isi-expand-icon]

Close
[IMG: isi-collapse-icon]

Tap for Important Safety Information. TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:

Expand
[IMG: isi-expand-white-icon]

Close
[IMG: isi-collapse-white-icon]

[H3] What is Trodelvy?
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.

[H3] IMPORTANT SAFETY INFORMATION
TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:
Low white blood cell count (neutropenia) is common and can sometimes be severe and lead to infections that can be life-threatening or cause death as early as the first cycle of treatment. Your healthcare provider should check your blood cell counts during treatment and may give a medicine to help prevent neutropenia starting in the first cycle of treatment if you have an increased risk for developing low white blood cell count with a fever (febrile neutropenia). If your white blood cell count is too low, your healthcare provider may need to delay treatment or lower your dose, give you a medicine to treat low blood cell count, or in some cases may permanently stop TRODELVY. Your healthcare provider may need to give you antibiotic medicines if you develop fever while your white blood cell count is low. Call your healthcare provider right away if you develop any of the following signs of infection: fever, chills, cough, shortness of breath, or burning or pain when you urinate.
Severe diarrhea. Diarrhea is common and can be severe. Severe diarrhea can lead to loss of too much body fluid (dehydration) and kidney problems. Your healthcare provider should monitor you for diarrhea and give you medicine as needed to help control it. If you lose too much body fluid, your healthcare provider may need to give you fluids and electrolytes to replace body salts. If you develop diarrhea during your treatment with TRODELVY, your healthcare provider should check to see if it may be caused by an infection. Your healthcare provider may decrease your dose, delay treatment, or permanently stop TRODELVY if your diarrhea is severe and cannot be controlled with anti-diarrheal medicines.
Call your healthcare provider right away the first time that you get diarrhea during treatment with TRODELVY; if you have black or bloody stools; if you have symptoms of dehydration, such as lightheadedness, dizziness, or faintness;

[H6]

[H3] WHAT IS TRODELVY?
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with:
triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.
hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body or cannot be removed by surgery, and who previously received endocrine therapy and at least two additional treatments for metastatic disease.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.
[H3] Important Safety Information
TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:
Low white blood cell count (neutropenia) is common and can sometimes be severe and lead to infections that can be life-threatening or cause death as early as the first cycle of treatment. Your healthcare provider should check your blood cell counts during treatment and may give a medicine to help prevent neutropenia starting in the first cycle of treatment if you have an increased risk for developing low white blood cell count with a fever (febrile neutropenia). If your white blood cell count is too low, your healthcare provider may need to delay treatment or lower your dose, give you a medicine to treat low blood cell count, or in some cases may permanently stop TRODELVY. Your healthcare provider may need to give you antibiotic medicines if you develop fever while your white blood cell count is low. Call your healthcare provider right away if you develop any of the following signs of infection: fever, chills, cough, shortness of breath, or burning or pain when you urinate.
Severe diarrhea. Diarrhea is common and can be severe. Severe diarrhea can lead to loss of too much body fluid (dehydration) and kidney problems. Your healthcare provider should monitor you for diarrhea and give you medicine as needed to help control it. If you lose too much body fluid, your healthcare provider may need to give you fluids and electrolytes to replace body salts. If you develop diarrhea during your treatment with TRODELVY, your healthcare provider should check to see if it may be caused by an infection. Your healthcare provider may decrease your dose, delay treatment, or permanently stop TRODELVY if your diarrhea is severe and cannot be controlled with anti-diarrheal medicines.
Call your healthcare provider right away the first time that you get diarrhea during treatment with TRODELVY; if you have black or bloody stools; if you have symptoms of dehydration, such as lightheadedness, dizziness, or faintness; if you are unable to take fluids by mouth due to nausea or vomiting; or if you are not able to get your diarrhea under control within 24 hours.

Do not receive TRODELVY if you have had a severe allergic reaction to TRODELVY. Ask your healthcare provider if you are not sure.
Allergic and infusion-related reactions which can be serious and life-threatening. Tell your healthcare provider or nurse right away if you get any of the following symptoms during your infusion of TRODELVY or within 24 hours after: swelling of your face, lips, tongue, or throat; hives; skin rash, itching, or flushing of your skin; fever; difficulty breathing or wheezing; lightheadedness, dizziness, feeling faint, or pass out; or chills or shaking chills (rigors).
Nausea and vomiting are common with TRODELVY and can sometimes be severe. Before each dose of TRODELVY, you will receive medicines to help prevent nausea and vomiting along with medicines to take home with instructions about how to take them. Call your healthcare provider right away if you have nausea or vomiting that is not controlled with the medicines prescribed for you. Your healthcare provider may decide to decrease your dose or stop TRODELVY if your nausea and vomiting is severe and cannot be controlled with anti-nausea medicines.
Before receiving TRODELVY, tell your healthcare provider about all of your medical conditions, including if you:
have been told that you carry a gene for UGT1A1*28, which can increase your risk of getting side effects with TRODELVY, especially low white blood cell counts, with or without a fever, and low red blood cell counts.
have liver problems.
are pregnant or plan to become pregnant. TRODELVY can harm your unborn baby. Your healthcare provider should check to see if you are pregnant before you start receiving TRODELVY. TRODELVY may cause fertility problems in females, which could affect your ability to have a baby. Talk to your healthcare provider if fertility is a concern for you.
Females who can become pregnant should use effective birth control during treatment and for 6 months after your last dose of TRODELVY. Talk to your healthcare provider about birth control choices that may be right for you during this time. Tell your healthcare provider right away if you become pregnant during treatment with TRODELVY.
Males with a female partner who can become pregnant should use effective birth control during treatment and for 3 months after your last dose of TRODELVY.

are breastfeeding or plan to breastfeed. It is not known if TRODELVY passes into your breastmilk and can harm your baby. Do not breastfeed during treatment and for 1 month after your last dose of TRODELVY.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the way TRODELVY works.
The most common side effects of TRODELVY include decreased white blood cell (leukocyte and lymphocyte) and red blood cell counts, feeling tired or weak, hair loss, constipation, increased sugar levels in the blood, decreased protein levels (albumin) in the blood, decreased appetite, changes in kidney function test, increased levels of enzyme called alkaline phosphatase in the blood (test for liver or bone problems), and decreased levels of magnesium, potassium, and sodium in the blood.
These are not all of the possible side effects of TRODELVY. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click to see Important Facts about TRODELVY, including Important Warning.

[H6]

[H2] You are now leaving TRODELVY.com

Click OK to proceed or Cancel to return to TRODELVY.com

[IMG: A Black woman in her early 40s wearing a paisley headscarf and a patterned yellow shirt sits in a brightly lit room at a round glass table smiling at her tablet screen, on a video call with her close group of friends. A potted plant, notebook, and notepad sit on the table with her. Actor portrayals.]

[H1] TRODELVY is designed to work differently than traditional chemo
Actor portrayals.

[H1] TRODELVY is designed to work differently than traditional chemo

Actor portrayals.

Listen to this page

00:00 / 00:00

[H2] TRODELVY targets cells with Trop-2
TRODELVY is a type of treatment called an antibody-drug conjugate (ADC). An ADC is a substance that binds to a specific protein or receptor found on certain types of cells, including cancer cells. Scientists discovered that tumor cells in certain cancers have a higher amount of proteins called Trop-2 than normal cells (or noncancer cells). TRODELVY is designed to bind to cells with Trop-2 and deliver powerful anticancer medicine.
Information from laboratory studies suggests that this is how TRODELVY works. The clinical benefit of these observations is unknown.

SEEKS OUT
TRODELVY attaches to Trop-2.

[IMG: A diagram showing 4 Y-shaped TRODELVY molecules attaching to the Trop-2 proteins on the outside of a cancer cell.]

[IMG: A diagram representing how TRODELVY enters the cancer cell.]

BREAKS IN
Once attached, TRODELVY enters the cancer cell.

DESTROYS
Once TRODELVY enters, the anticancer medicine is released, killing the cell.

[IMG: A diagram showing a cancer cell breaking apart as TRODELVY releases the anticancer medicine from inside the cell.]

[H2] How TRODELVY works
Understanding what makes each treatment different can be confusing. This video will help break down the science to show you how TRODELVY is designed to work. Think of TRODELVY like a cargo ship designed to deliver anticancer medicine directly into cells with Trop-2 proteins. Watch to learn about TRODELVY from an oncologist and some unexpected guests.

English
Español

<TEXT ON-SCREEN>
HOW TRODELVY IS DESIGNED TO WORK
TRODELVY®
sacituzumab govitecan-hziy
180 mg for injection
WHAT IS TRODELVY?
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with:
triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.
hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body or cannot be removed by surgery, and who previously received endocrine therapy and at least two additional treatments for metastatic disease.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.
IMPORTANT SAFETY INFORMATION
TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:
Low white blood cell count (neutropenia) is common and can sometimes be severe and lead to infections that can be life-threatening or cause death as early as the first cycle of treatment. Your healthcare provider should check your blood cell counts during treatment and may give a medicine to help prevent neutropenia starting in the first cycle of treatment if you have an increased risk for developing low white blood cell count with a fever (febrile neutropenia). If your white blood cell count is too low, your healthcare provider may need to delay treatment or lower your dose, give you a medicine to treat low blood cell count, or in some cases may permanently stop TRODELVY. Your healthcare provider may need to give you antibiotic medicines if you develop fever while your white blood cell count is low. Call your healthcare provider right away if you develop any of the following signs of infection: fever, chills, cough, shortness of breath, or burning or pain when you urinate.
Severe diarrhea. Diarrhea is common and can be severe. Severe diarrhea can lead to loss of too much body fluid (dehydration) and kidney problems. Your healthcare provider should monitor you for diarrhea and give you medicine as needed to help control it. If you lose too much body fluid, your healthcare provider may need to give you fluids and electrolytes to replace body salts. If you develop diarrhea during your treatment with TRODELVY, your healthcare provider should check to see if it may be caused by an infection. Your healthcare provider may decrease your dose, delay treatment, or permanently stop TRODELVY if your diarrhea is severe and cannot be controlled with anti-diarrheal medicines.
Call your healthcare provider right away the first time that you get diarrhea during treatment with TRODELVY; if you have black or bloody stools; if you have symptoms of dehydration, such as lightheadedness, dizziness, or faintness; if you are unable to take fluids by mouth due to nausea or vomiting; or if you are not able to get your diarrhea under control within 24 hours.
Do not receive TRODELVY if you have had a severe allergic reaction to TRODELVY. Ask your healthcare provider if you are not sure.
Please continue watching for Important Safety Information at the end of this video and please see link provided for Important Facts, including Important Warning.
The actors portrayed in this video are not actual TRODELVY patients. They are here for your education and entertainment. Enjoy.
<END OF TEXT ON-SCREEN>
Crystal:
I’m an info nerd. UFO sightings, beekeeping, or Barry Manilow’s greatest hits, you name it, I know it. So when I got my metastatic cancer diagnosis, I wanted to know everything I could about treatment options.
<TEXT ON-SCREEN>
TRODELVY®
sacituzumab govitecan-hziy
180 mg for injection
<END OF TEXT ON-SCREEN>
Right now, I’m looking at some firsthand experience with TRODELVY sacituzumab govitecan-hziy?
<TEXT ON-SCREEN>
sacituzumab govitecan-hziy
<END OF TEXT ON-SCREEN>
Is that a word? Has anyone here tried it?
<TEXT ON-SCREEN>
CRYSTAL
Curious about TRODELVY
Self-proclaimed Info Nerd
<END OF TEXT ON-SCREEN>
<TEXT ON-SCREEN>
TRODELVY? I haven’t tried that yet.
I’ll have to talk to my doctor about that one.
My doctor mentioned TRODELVY, but I haven’t looked into it.
I’ve been taking TRODELVY for three months now. What’s on your mind?
I’ve heard about TRODELVY but need to find more info too. Let me know what you learn.
<END OF TEXT ON-SCREEN>
Amanda:
I’ve been taking TRODELVY for 3 months now. What’s on your mind?
<TEXT ON-SCREEN>
AMANDA
TRODELVY Patient and Champion
<END OF TEXT ON-SCREEN>
Crystal:
I’ve probably got 100 questions, but how exactly does it work?
Amanda:
My doctor told me it delivers anticancer medicine into cells... But how it does that… I’m lousy at explaining things. Hold on one moment.
<TEXT ON-SCREEN>
My doctor told me it delivers anticancer medicine into cells…
<END OF TEXT ON-SCREEN>
<TEXT ON-SCREEN>
DR. ESPOSITO
Oncologist
(Has no idea she’s on mute)
<END OF TEXT ON-SCREEN>
Amanda:
You’re on mute.
Dr. Esposito:
Sorry. Anyway, hey. I’m an oncologist. It is so good to see yo